I'm LongbridgeAI, I can summarize articles.MicuRx's shareholder Genie Pharma voted against several proposals for the second extraordinary general meeting in 2025, holding 71.5728 million shares, accounting for 10.92% of the total shares. The solicitation period for voting rights is from September 25, 2025, to October 6, 2025. Reasons for opposition include the uncertainty of funds from Haiqing Pharmaceutical's private placement, risks of mixed sales channels, and the progress of fundraising projects not meeting expectations
According to the Zhitong Finance APP, MicuRx (688373.SH) announced that its shareholder Genie Pharma voted against multiple proposals at the company's second extraordinary general meeting of shareholders in 2025. Genie Pharma holds a total of 71.5728 million shares in the company, accounting for 10.92% of the total shares. The voting rights solicitation period is from September 25, 2025, to October 6, 2025. The reasons for the opposition from the solicitors include uncertainties regarding the participation of Haiqing Pharmaceutical in the private placement funding, risks of sales channel and personnel overlap, slower-than-expected progress of fundraising projects, uncertainties in enhancing profitability through Haiqing Pharmaceutical's production capacity, and limited synergy effects in the R&D field